IPF diagnosis, treatment and quality of life study
Part of Lungs & breathing clinical trials.
This study looks at how idiopathic pulmonary fibrosis (IPF) is diagnosed and treated, and how it affects patients' daily lives. It aims to learn from both patients and their doctors to improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with IPF by a doctor using standard guidelines.
- You are able to clearly express your thoughts and feelings.
- Your doctor is an expert in treating IPF and has lots of experience.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people with idiopathic pulmonary fibrosis (IPF) who are currently having a sudden worsening of breathing symptoms. It may help doctors better understand what happens during these flare-ups and how to manage them.
This study is looking at people with Idiopathic Pulmonary Fibrosis (IPF), a type of lung scarring. Researchers will use medical records to see if they can better predict how the disease will progress over time.
This study builds a community registry to learn about people affected by pulmonary fibrosis and related lung conditions, including patients, caregivers, and close family. By joining, you help researchers better understand needs and experiences in the real world.
This trial is for people with scarring lung disease (pulmonary fibrosis) in Ireland. It aims to better understand and care for the condition, especially in families. The study will look at medical data and may help improve diagnosis and treatment.
This study looks at genetic (DNA) and protein changes over time in people with idiopathic pulmonary fibrosis, to better understand how the disease progresses. Your participation may help researchers learn patterns that could guide future care.
This trial tests a new medicine, BI 765423, to see if it can improve lung function in people with IPF, a lung scarring disease. You can join whether or not you are already taking standard treatments like nintedanib or pirfenidone.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.